drugset / Trial / NCT00256126

Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®

NCT00256126

Phase 4 Completed 318 enrolled Merck KGaA, Darmstadt, Germany
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study aims at identifying the predictive markers after one month of Saizen therapy in Growth Hormone Deficiency (GHD) and Turner Syndrome children.

Timeline

Start
2005-05-31
Primary completion
2007-09-30
Completion
2007-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 0.035 mg/kg Subcutaneous
Subject Somatropin Protein / enzyme biologic 0.05 mg/kg Subcutaneous